Mumps vaccine failure investigation in Novosibirsk, Russia, 2002-2004

Clinical Microbiology and Infection

Volumn 13, Issue 7, 2007, Pages 670-676

  Atrasheuskaya, A V ^a   Kulak, M V ^a   Rubin, S ^b   Ignatyev, G M ^a  

^a STATE RESEARCH CENTER OF VIROLOGY AND BIOTECHNOLOGY VECTOR   (Russian Federation)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Genotyping; Mumps virus; Russia; Serology; Vaccine failure

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MUMPS VACCINE; NEUTRALIZING ANTIBODY; VIRUS RNA;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; FEMALE; GENE AMPLIFICATION; GENE SEQUENCE; GENOTYPE; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MUMPS; MUMPS VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RUSSIAN FEDERATION; SEQUENCE ANALYSIS; SEROCONVERSION; SEROLOGY; VACCINATION; VACCINE FAILURE; VIRUS NEUTRALIZATION; VIRUS STRAIN;

MUMPS VIRUS;

EID: 34250303109     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01727.x     Document Type: Article

References (36)

1. Gut J-P, Lablache C, Behr S, Kirn A. Symptomatic mumps reinfections. J Med Virol 1995; 45: 17-23.
2. Crowley B, Afzal MA. Mumps virus reinfection - clinical findings and serological vagaries. Comm Dis Public Health 2002; 5: 311-313.
3. Anonymous. Mumps epidemic - United Kingdom, 2004-2005. CDC. MMWR 2006; 55: 173-175.
4. Anonymous. USA - mumps activity update; 1 January to 7 October 2006. CDC. MMWR 2006; 55: 1152-1153.
5. Hersh BS, Fine PEM, Kent W et al. Mumps outbreak in a highly vaccinated population. J Pediatr 1991; 119: 187-193.
6. Briss PA, Fehrs LJ, Parker RA et al. Sustained transmission of mumps in a highly vaccinated population: Assessment of primary vaccine failure and waning vaccine-induced immunity. J Infect Dis 1994; 169: 77-82.
7. Strohle A, Eggenberger K, Steiner CA, Matter L, Germann D. Mumps epidemic in vaccinated children in West Switzerland. Schweiz Med Wochenschr 1997; 127: 1124-1133.
8. Vandermeulen C, Roelants M, Vermoere M, Roseeuw K, Goubau P, Hoppenbrouwers K. Outbreak of mumps in a vaccinated child population: A question of vaccine failure. Vaccine 2004; 22: 2713-2716.
9. Örvell C, Alsheikhly A-R, Kalantari M, Johansson B. Characterization of genotype-specific epitopes of the HN protein of mumps virus. J Gen Virol 1997; 78: 3187-3193.
10. Nöjd J, Tecle T, Samuelsson A, Örvell C. Mumps virus neutralizing antibodies do not protect against reinfection with a heterologous mumps virus genotype. Vaccine 2001; 19: 1727-1731.
11. Agafonov AP, Nicheuchina SN, Patrusheva I et al. Characteristics of parotitis virus, isolated in Siberia. Vopr Virusol 1997; 42: 222-226.
12. Agafonov AP, Streltsova MA, Suslaparov IM, Ignatyev GM. Immune parameters in mumps patients. Vopr Virusol 2001; 1: 30-33.
13. Heider A, Ignatyev G, Gerike E, Schreier E. Genotypic characterization of mumps virus isolated in Russia (Siberia). Res Virol 1997; 148: 433-435.
14. Nesterov AE, Kameneva CN, Maksimov NL, Ignatyev GM. Lymphadenopathy in a previously vaccinated patient with mumps. Infect Dis 2004; 4: 92-94.
15. Utz S, Richard JL, Capaul S, Matter HC, Hrisoho MG, Muhlemann K. Phylogenetic analysis of clinical mumps virus isolates from vaccinated and non-vaccinated patients with mumps during an outbreak, Switzerland 1998-2000. J Med Virol 2004; 73: 91-96.
16. Narita M, Matsuzono Y, Takekoshi Y et al. Analysis of mumps vaccine failure by means of avidity testing for mumps virus-specific immunoglobulin G. Clin Diagn Lab Immunol 1998; 5: 799-803.
17. Davidkin I, Jokinen S, Paananen A, Leinikki P, Peltola H. Etiology of mumps-like illness in children and adolescents vaccinated for measles, mumps, and rubella. J Infect Dis 2005; 191: 719-723.
18. Kunkel U, Driesel G, Henning U, Gerike E, Willers H, Schreier E. Differentiation of vaccine and wild mumps viruses by polymerase chain reaction and nucleotide sequencing of the SH gene: Brief report. J Med Virol 1995; 45: 121-126.
19. Elliott GD, Afzal MA, Martin SJ, Rima BK. Nucleotide sequence of the matrix, fusion and putative SH protein genes of MuV and their deduced amino acid sequences. Virus Res 1989; 12: 61-75.
20. Paunio M, Hedman K, Davidkin I, Peltola H. IgG avidity to distinguish secondary from primary measles vaccination failures: Prospects for a more effective global measles elimination strategy. Expert Opin Pharmacother 2003; 4: 1215-1225.
21. Muhlemann K. The molecular epidemiology of mumps virus. Infect Genet Evol 2004; 4: 215-219.
22. Atrasheuskaya AV, Neverov AA, Rubin S, Ignatyev GM. Horizontal transmission of the Leningrad-3 live attenuated mumps vaccine virus. Vaccine 2006; 24: 1530-1536.
23. Rizzo LV, DeKruyff RH, Umetsu DT. Generation of B cell memory and affinity maturation. Induction with Th1 and Th2 T cell clones. J Immunol 1992; 148: 3733-3739.
24. Lazzarotto T, Varani S, Spezzacatena P et al. Delayed acquisition of high-avidity anti-cytomegalovirus antibody is correlated with prolonged antigenemia in solid organ transplant recipients. J Infect Dis 1998; 178: 1145-1149.
25. Weissbrich B. The use of semi-automated EBV IgG avidity determination for the diagnosis of infectious mononucleosis. J Med Virol 1998; 54: 145-153.
26. Atrasheuskaya AV, Blatun EM, Neverov AA, Karpov IA, Ignatyev GM. Measles in Minsk, Belarus, 2001-2003: Clinical, virological and serological parameters. J Clin Virol 2005; 34: 179-185.
27. Paunio M, Hedman K, Davidkin I, Peltola H. IgG avidity to distinguish secondary from primary measles vaccination failures: Prospects for a more effective global measles elimination strategy. Exp Opinion 2003; 4: 1215-1225.
28. WHO. Global status of mumps immunization and surveillance. Wkly Epidemiol Record 2005; 48: 417-424.
29. Sanz-Moreno JC, Limia-Sanchez A, Garcia-Comas L et al. Detection of secondary mumps vaccine failure by means of avidity testing for specific immunoglobulin G. Vaccine 2005; 23: 4921-4925.
30. Harling R, White JM, Ramsay ME, Macsween KF, van den Bosch C. The effectiveness of the mumps component of the MMR vaccine: A case control study. Vaccine 2005; 23: 4070-4074.
31. Rubin S, Mauldin J, Chumakov K, Vanderzanden J, Iskow R, Carbone K. Serological and phylogenetic evidence of monotypic immune responses to different mumps virus strains. Vaccine 2006; 24: 2662-2668.
32. Muller CP, Huiss S, Schneider F. Secondary immune responses in parents of children with recent measles. Lancet 1996; 348: 1379-1380.
33. Huiss S, Damien B, Schneider F, Muller CP. Characteristics of asymptomatic secondary immune response to measles virus in late convalescent donors. Clin Exp Immunol 1997; 109: 416-420.
34. Bautista-Lopez N, Ward BJ, Mills E, McCormick D, Martel N, Ratnam S. Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination. Vaccine 2000; 18: 1393-1401.
35. + T cells in subjects seronegative or highly seropositive for measles vaccine. Clin Diagn Lab Immunol 2003; 10: 411-416.
36. Pipkin PA, Afzal MA, Heath AB, Minor PD. Assay of humoral immunity to mumps virus. J Virol Methods 1999; 79: 219-215.